Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo

FDA Slams Hims & Hers With A Warning Letter. Investors Slam Hims Stock.

Hims stock toppled Tuesday after the FDA issued the telehealth giant a warning letter regarding its knockoff version of semaglutide.

Investors Business Daily

Novo Nordisk Tightens Its Belt, Cutting 9,000 Jobs And Its Profit Outlook

Novo Nordisk announced a "sweeping transformation" Wednesday as the drugmaker contends with knockoffs chipping away at its blockbuster drugs.

Investors Business Daily

Novo Nordisk to cut 9,000 jobs as Eli Lilly competition intensifies

The pharmaceutical giant will axe over 11% of its global workforce as rival Eli Lilly gathers market share in the obesity drug market.

Euronews

From analysis to the latest developments in health,
read the most diverse news in one place.

Weight loss drugmaker to slash 9,000 jobs in £926 million cost cut

Novo Nordisk was at one point last year Europe's most valuable listed company

The Independent UK

Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary'

Novo Nordisk (NYSE:NVO) has announced a significant restructuring plan that will see the company cut 9,000 jobs, representing 11.5% of its workforce. The decision comes as the pharmaceutical giant faces mounting pressure from U.S. competitor Eli Lilly (NYSE:LLY).

Benzinga

FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk

The FDA signed off on the first-ever weight-loss generic on Thursday, a knockoff of Novo Nordisk's Saxenda from Teva Pharmaceutical.

Investors Business Daily

Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure

Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment. Can it make a comeback?

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data

Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are expected to launch new obesity-treatment pills in the U.S. next year at prices comparable to their existing injectable drugs, signaling a break from the industry trend of charging more for new therapies.

Benzinga

GoodRx Holdings Surges 5% After Hours on Novo Nordisk Partnership for $499 Monthly Ozempic, Wegovy Access

GoodRx Holdings Inc. (NASDAQ:GDRX) shares jumped 5.08% in after-hours trading on Monday, following the announcement of a collaboration with Novo Nordisk A/S (NYSE:NVO) to offer discounted GLP-1 medications at fixed pricing nationwide.

Benzinga

Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4

A chip stock that recently partnered with NVIDIA. Now, a key company insider is buying over $160 million in shares, a bullish signal to investors.

MarketBeat

GoodRx Is Soaring on a Novo Nordisk Deal. Should You Buy GDRX Stock Here?

GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX shares into the strength before they crash again.

Barchart

Novo Nordisk slashes price of Ozempic in half to $499 for cash-paying, eligible U.S. patients

The previous out-of-pocket price was nearly $1,000.

Fortune

Novo Nordisk Rallied On Wegovy's Newest Approval. But This Rival Rallied More.

Novo Nordisk stock jumped Monday after the FDA approved the company's obesity drug, Wegovy, as a treatment for MASH.

Investors Business Daily

Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?

Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone.

MarketBeat

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

This Blue-Chip Stock Is Cooking Up a Major Growth Catalyst

Eli Lilly is poised for a major boost as new data shows its diabetes drug Mounjaro offers heart health benefits, potentially making it the top choice for patients with Type 2 diabetes.

The Independent UK

‘Shock’ as study reveals how weight-loss pill stacks up against injections

Shares in a pharmaceutical company plummeted after the results were made public

Investors Business Daily

Eli Lilly Dives 14% On A Shocking Obesity Setback, Sending Its Rivals Flying

Eli Lilly stock tumbled Thursday on an unexpected setback for its obesity franchise, sending shares of its rival flying.

Investors Business Daily

Novo Nordisk Slumps As 'Unlawful' Knockoffs Pressure Wegovy, Ozempic

Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, Wegovy.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Ozempic Maker Novo Nordisk Terminates Multiple Pipeline Programs, Faces Investor Lawsuit Over GLP-1 Market Misrepresentation

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish kroner), missing the consensus of $11.79 billion.

Euronews

Novo Nordisk keeps growing, fuelling hopes of a stock rebound

Novo Nordisk reported 18% sales growth in the first half of 2025, despite a profit warning that triggered a record share drop. Goldman Sachs says the sell-off is overdone and analysts highlight a potential buying opportunity.

Barchart

Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?

With Novo Nordisk shedding double digits following its latest guidance cut, is this a chance to buy the dip or a warning sign of deeper trouble ahead?

MarketBeat

Will Hims & Hers Fall Along With Novo Nordisk?

Novo Nordisk shares are trading as low as 35% of their 52-week highs, making Hims & Hers investors nervous whether a selloff is coming.

Benzinga

Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% year-over-year, beating the consensus of $8.57.

The Guardian - US

Trump officials plan coverage for weight loss drugs under Medicare and Medicaid

Pilot program, first pitched under Biden, will cover GLP-1 drugs such as Ozempic to address chronic obesity in US

Barchart

Should You Buy the Post-Earnings Plunge in Novo Nordisk Stock or Stay Far, Far Away?

Novo Nordisk is a healthcare stock that is down 50% in 2025. Is NVO stock undervalued at current levels or can it move lower over the next 12 months?

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.